Prne
September 21st, 2009
HUNTINGTON BEACH, California and AMSTERDAM -
- Company to Present at UBS Global Life Sciences Conference on Sept. 23
Agendia, a world leader in molecular cancer diagnostics, today announced the successful closing of a US $23 million series E investment. The financing round was led by an undisclosed family investment firm that provided approximately half of the funds. In addition, two independent entrepreneurs participated with an investment of US $1 million each, while the remaining capital was raised through Agendia’s existing investor base.
“The success of this financing round was aided by MammaPrint(R)’s increasing U.S. demand, as well as growing reimbursement from private U.S. payors. The proceeds will be used to accelerate the commercialization of MammaPrint in the U.S. market,” said Dr. Bernhard Sixt, President and Chief Executive Officer of Agendia.
“We are excited to be a part of Agendia’s continued growth and to enable the company to bolster its strategic marketing and sales efforts as it brings MammaPrint to an ever increasing number of breast cancer patients,” said Gertjan van der Baan, Board Member on behalf of van Herk Group, Agendia’s largest investor.
Dr. Sixt will present at the UBS Global Life Sciences Conference on Wednesday, September 23, 2009 at 1 p.m. (ET) in Ballroom D at the Grand Hyatt in New York.
About MammaPrint(R)
MammaPrint is the first ‘in vitro diagnostic multivariate index assay’ (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.
All MammaPrint tests are conducted in Agendia’s CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.
About Agendia
Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company’s tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.
Source: Agendia B.V.
Hans Herklots, Head of Corporate Communications, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots at agendia.com; Valerie Delva, Account Executive, Ricochet Public Relations, +1-212-679-3300 x131 Office, vdelva at ricochetpr.com
Filed under Banking and Financial Services, Biotechnology, Financing Agreements, Health, Health Care / Hospitals, Pharmaceuticals | Tags: Agendia B.V., Californiaamsterdam, Huntington beach, Netherlands, United States of America | Comment Below
Related Press Releases ProFibrix Raises US $11 Million (EUR 8 Million) in Series B FinancingAugust 23rd, 2009 LEIDEN, The Netherlands and SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Rayspan Raises US$12.5 million in Series B Financing from Khosla Ventures & Sequoia CapitalJuly 26th, 2009 SAN DIEGO -
Rayspan Corporation, the world's leading innovator of metamaterial air interface solutions for wireless communications, today announced that it has received US$12.5M in a Series B financing led by new investor Khosla Ventures, who was joined by existing Rayspan investor Sequoia Capital as well as individual private investors. The financing will be utilized by Rayspan to accelerate and expand the development and commercialization of its breakthrough metamaterial wireless technology. Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus RecommendationsJune 22nd, 2009 HUNTINGTON BEACH, California and AMSTERDAM - International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility
Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence test MammaPrint in St. Gallen's 2009 International Expert Consensus on the primary therapy of early breast cancer. Agendia Supports Genentech's Citizen's Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory StandardsMay 27th, 2009 HUNTINGTON BEACH, California, and AMSTERDAM - Agendia, a world leader in molecular cancer diagnostics, today announced its strong support of Genentech's Citizen's Petition. Filed on December 5, 2008, Docket No. Tigo Energy Reaches Key Milestones and Raises US$10 Million 'B' Round FinancingMay 26th, 2009 LOS GATOS, California - Tigo Energy, (www.tigoenergy.com), the solar company whose unique technology significantly increases efficiency in photovoltaic solar installations, announced today that it has closed the second round of funding. The US$10 million round was led by ICV, and joined by all existing investors (Matrix Partners, OVP and Clal Energy). Agendia Opens CLIA-Registered U.S. Genomics LaboratoryMay 25th, 2009 HUNTINGTON BEACH, California and AMSTERDAM - Agendia Increases U.S. Footprint with Domestic Executive Team and Operations
Agendia, a world leader in molecular cancer diagnostics, today announced the opening of its U.S. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual MeetingMay 20th, 2009 HUNTINGTON BEACH, California and AMSTERDAM - Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida. The study results further underpin the broad predictive and prognostic power of Agendia's breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia's new colon cancer recurrence test, ColoPrint(TM). Cell Biosciences Closes US$10 Million Series C FinancingApril 8th, 2009 PALO ALTO, California - Cell Biosciences, a provider of nanoproteomic analysis systems to life science researchers, today announced the closing of a US$10 million Series C financing led by its largest shareholder, the Wellcome Trust. Existing investors Domain Associates, Latterell Venture Partners, Novo A/S, Mitsui Ventures, Royal Bank of Canada and The Vertical Group also participated in the financing. Agendia to Present at BioCentury's Future Leaders in the Biotech Industry ConferenceMarch 23rd, 2009 HUNTINGTON BEACH, California and AMSTERDAM - Agendia, a world leader in molecular cancer diagnostics, today
announced that the Company is scheduled to present at the 16th Anniversary
"Future Leaders in the Biotech Industry" Conference on Thursday, April 2,
2009. Presented by BioCentury and Thomson Reuters, the Future Leaders
conference has built a reputation as a major biotech investment event,
matching strong companies with a select group of specialized institutional
investors, investment bankers, sellside/buyside analysts, and pharmaceutical
licensing executives. Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer ConferenceMarch 10th, 2009 HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands - Agendia, a world leader in molecular cancer diagnostics, today
announced that leading researchers from Agendia and the Netherlands Cancer
Institute will present data from multiple studies at the 2009 St.Gallen
Breast Cancer Conference. The St. Gallen Breast Cancer Conference, one of the
premiere conferences in breast cancer research worldwide, takes place March
11th-14th, 2009 in St.Gallen, Switzerland.
Related News AbitibiBowater needs debtor financing, bankruptcy court toldMay 2nd, 2009 AbitibiBowater needs debtor financingMONTREAL — Insolvent U.S. newsprint maker AbitibiBowater says it desperately needs a cash infusion from debtor financing after losing $2.2 billion last year. Visteon attorney says company making good progress on bankruptcy financingJune 19th, 2009 Attorney says Visteon making progress on financingWILMINGTON, Del. — Auto-parts supplier Visteon Corp. US Airways offering of 29 million shares raises $137.3 millionSeptember 30th, 2009 US Airways raises $137.3 million in stock offeringTEMPE, Ariz. — US Airways Group Inc. Judge gives final approval to GM's use of bankruptcy financingJune 25th, 2009 Judge gives final OK to bankruptcy financingNEW YORK — A bankruptcy judge says GM can have access to its full $33.3 billion in bankruptcy financing. Judge Robert Gerber gave final approval to the financing on Thursday. CarMax renews, lowers warehouse facility for financing arm by $200MAugust 7th, 2009 CarMax renews, lowers warehouse facilityRICHMOND, Va. — Automotive retailer CarMax Inc. Bankruptcy judge gives interim approval for GM to access $33.3 billion in financingJune 2nd, 2009 Judge OKs use of GM bankruptcy financingNEW YORK — A bankruptcy judge says General Motors can have immediate access to $15 billion in government financing as it attempts to quickly restructure under court protection. U.S. Judge Robert Gerber gave interim approval to the Detroit-based automaker's use of a total of $33.3 billion in financing, with the $15 billion available for use over the next three weeks. Optical equipment maker Oclaro raises outlook for its 1st-qtr revenue to $82M to $87MSeptember 21st, 2009 Oclaro raises outlook for its 1Q revenueSAN JOSE, Calif. — Oclaro Inc. Janus says repurchase offer expires, raises cap to $444 millionAugust 12th, 2009 Janus says tender offer expires, raises offer capDENVER — Janus Capital Group Inc. on Wednesday said its offer to repurchase outstanding notes has expired and it has raised the repurchase amount after a better-than-expected response from investors. Southwest reaches tentative contract with pay raises for 5,300 customer-service repsMay 5th, 2009 Southwest Airlines labor deal includes pay raisesDALLAS — Southwest Airlines Co. says it has reached a tentative agreement that gives pay raises to customer-service employees. Chrysler Financial to immediately stop dealer wholesale financingMay 2nd, 2009 Chrysler Financial to suspend dealer financingFARMINGTON, Mich. — Chrysler Financial says it's temporarily suspending financing for Chrysler dealers effective immediately.
|
|
